Latest Content

CURE recently spoke with CEPHEUS study investigator Dr. Saad Z. Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center.

A gynecologic oncologist discusses staging, treatment choices, sexual health, mental health and HPV vaccination during cervical cancer awareness month.

Dr. Suneel Kamath addresses patient concerns on the topic of clinical trial participation in the gastrointestinal cancer treatment space.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

Losing my cat after years alongside my cancer journey reminded me how much his presence eased stress, anxiety and treatment days.

The FDA accepted a new drug application for zanzalintinib plus immunotherapy after showing improved survival in some previously treated colorectal cancers.

An expert explains FDA-approved Lymphir for relapsed or refractory CTCL, noting 36% response rate, manageable side effects and fast relief from itching.

A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic castration-sensitive prostate cancer.

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Biotin supplements used for cancer-related hair loss may interfere with key blood tests, risking inaccurate results and altered care decisions.

Minimal residual disease testing can offer psychological comfort to patients and survivors as well as insight into potential treatment strategies for care providers.

Stage 2 ccRCC is treated with surgery, and patients should discuss partial nephrectomy, adjuvant therapy, and follow-up care with their oncology team.